Cargando…

Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries?

Diabetes is a rapidly growing global health crisis disproportionately affecting low- and middle-income countries (LMICs). The emergence of diabetes as a global pandemic is one of the major challenges to human health, as long-term microvascular complications such as diabetic retinopathy (DR) can lead...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizvi, Anza, Rizvi, Fatima, Lalakia, Parth, Hyman, Leslie, Frasso, Rosemary, Sztandera, Les, Das, Anthony Vipin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586227/
https://www.ncbi.nlm.nih.gov/pubmed/37868419
http://dx.doi.org/10.7759/cureus.45539
_version_ 1785123113618374656
author Rizvi, Anza
Rizvi, Fatima
Lalakia, Parth
Hyman, Leslie
Frasso, Rosemary
Sztandera, Les
Das, Anthony Vipin
author_facet Rizvi, Anza
Rizvi, Fatima
Lalakia, Parth
Hyman, Leslie
Frasso, Rosemary
Sztandera, Les
Das, Anthony Vipin
author_sort Rizvi, Anza
collection PubMed
description Diabetes is a rapidly growing global health crisis disproportionately affecting low- and middle-income countries (LMICs). The emergence of diabetes as a global pandemic is one of the major challenges to human health, as long-term microvascular complications such as diabetic retinopathy (DR) can lead to irreversible blindness. Leveraging artificial intelligence (AI) technology may improve the diagnostic accuracy, efficiency, and accessibility of DR screenings across LMICs. However, there is a gap between the potential of AI technology and its implementation in clinical practice. The main objective of this systematic review is to summarize the currently available literature on the health economic assessments of AI implementation for DR screening in LMICs. The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We conducted an extensive systematic search of PubMed/MEDLINE, Scopus, and the Web of Science on July 15, 2023. Our review included full-text English-language articles from any publication year. The Joanna Briggs Institute's (JBI) critical appraisal checklist for economic evaluations was used to rate the quality and rigor of the selected articles. The initial search generated 1,423 records and was narrowed to five full-text articles through comprehensive inclusion and exclusion criteria. Of the five articles included in our systematic review, two used a cost-effectiveness analysis, two used a cost-utility analysis, and one used both a cost-effectiveness analysis and a cost-utility analysis. Across the five articles, LMICs such as China, Thailand, and Brazil were represented in the economic evaluations and models. Overall, three out of the five articles concluded that AI-based DR screening was more cost-effective in comparison to standard-of-care screening methods. Our systematic review highlights the need for more primary health economic analyses that carefully evaluate the economic implications of adopting AI technology for DR screening in LMICs. We hope this systematic review will offer valuable guidance to healthcare providers, scientists, and legislators to support appropriate decision-making regarding the implementation of AI algorithms for DR screening in healthcare workflows.
format Online
Article
Text
id pubmed-10586227
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105862272023-10-20 Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries? Rizvi, Anza Rizvi, Fatima Lalakia, Parth Hyman, Leslie Frasso, Rosemary Sztandera, Les Das, Anthony Vipin Cureus Ophthalmology Diabetes is a rapidly growing global health crisis disproportionately affecting low- and middle-income countries (LMICs). The emergence of diabetes as a global pandemic is one of the major challenges to human health, as long-term microvascular complications such as diabetic retinopathy (DR) can lead to irreversible blindness. Leveraging artificial intelligence (AI) technology may improve the diagnostic accuracy, efficiency, and accessibility of DR screenings across LMICs. However, there is a gap between the potential of AI technology and its implementation in clinical practice. The main objective of this systematic review is to summarize the currently available literature on the health economic assessments of AI implementation for DR screening in LMICs. The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We conducted an extensive systematic search of PubMed/MEDLINE, Scopus, and the Web of Science on July 15, 2023. Our review included full-text English-language articles from any publication year. The Joanna Briggs Institute's (JBI) critical appraisal checklist for economic evaluations was used to rate the quality and rigor of the selected articles. The initial search generated 1,423 records and was narrowed to five full-text articles through comprehensive inclusion and exclusion criteria. Of the five articles included in our systematic review, two used a cost-effectiveness analysis, two used a cost-utility analysis, and one used both a cost-effectiveness analysis and a cost-utility analysis. Across the five articles, LMICs such as China, Thailand, and Brazil were represented in the economic evaluations and models. Overall, three out of the five articles concluded that AI-based DR screening was more cost-effective in comparison to standard-of-care screening methods. Our systematic review highlights the need for more primary health economic analyses that carefully evaluate the economic implications of adopting AI technology for DR screening in LMICs. We hope this systematic review will offer valuable guidance to healthcare providers, scientists, and legislators to support appropriate decision-making regarding the implementation of AI algorithms for DR screening in healthcare workflows. Cureus 2023-09-19 /pmc/articles/PMC10586227/ /pubmed/37868419 http://dx.doi.org/10.7759/cureus.45539 Text en Copyright © 2023, Rizvi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Ophthalmology
Rizvi, Anza
Rizvi, Fatima
Lalakia, Parth
Hyman, Leslie
Frasso, Rosemary
Sztandera, Les
Das, Anthony Vipin
Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries?
title Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries?
title_full Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries?
title_fullStr Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries?
title_full_unstemmed Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries?
title_short Is Artificial Intelligence the Cost-Saving Lens to Diabetic Retinopathy Screening in Low- and Middle-Income Countries?
title_sort is artificial intelligence the cost-saving lens to diabetic retinopathy screening in low- and middle-income countries?
topic Ophthalmology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586227/
https://www.ncbi.nlm.nih.gov/pubmed/37868419
http://dx.doi.org/10.7759/cureus.45539
work_keys_str_mv AT rizvianza isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries
AT rizvifatima isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries
AT lalakiaparth isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries
AT hymanleslie isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries
AT frassorosemary isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries
AT sztanderales isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries
AT dasanthonyvipin isartificialintelligencethecostsavinglenstodiabeticretinopathyscreeninginlowandmiddleincomecountries